Experts are discussing the effectiveness and safety of microdosing GLP-1s, such as semaglutide and Ozempic, for weight loss. The benefits and risks of this approach are being debated, with some outlets reporting on the potential for weight loss and others highlighting concerns about safety. Some studies suggest that a portion of individuals may be able to maintain weight loss after stopping GLP-1 drugs, but opinions on microdosing appear to be divided among experts.